If you're running a telehealth company that dispenses compounded medications — especially peptides and GLP-1 injectables — the distinction between 503A and 503B compounding isn't academic. It determines who you can partner with, how your prescriptions get filled, what your supply chain looks like, and what regulatory risks you carry.
The Two Frameworks
Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) define two distinct legal pathways for compounding medications that are not commercially available as FDA-approved products.
503A — Traditional Compounding Pharmacies
A 503A pharmacy is a state-licensed pharmacy that compounds medications based on individual patient prescriptions from a licensed prescriber. Each compound is prepared for a specific, named patient; there must be a valid prescriber-patient relationship; the pharmacy operates under state board of pharmacy oversight; and the compound is exempt from FDA new drug approval and labeling requirements, as long as it meets 503A conditions.
503B — Outsourcing Facilities
503B outsourcing facilities were created by the Drug Quality and Security Act of 2013, largely in response to the 2012 New England Compounding Center meningitis outbreak that killed 76 people. 503B facilities can compound without patient-specific prescriptions — they produce batch quantities distributed to healthcare facilities. The tradeoff: much heavier FDA oversight, including facility registration, regular inspections, adverse event reporting, and cGMP compliance.
The Practical Differences That Matter
Prescription Requirements
503A: Every compound requires an individual prescription for a named patient. Your telehealth prescriber writes Rx → pharmacy compounds for that specific patient → ships to patient. This is the standard DTC telehealth model.
503B: No individual prescription required. The facility compounds batches distributed to healthcare providers who then administer or dispense to patients. Think: a clinic that keeps compounded peptide vials in stock.
What this means for telehealth: If your model is prescriber-to-patient (home delivery), you're working with 503A pharmacies. If your model involves clinics that stock and administer on-site, 503B may be relevant.
Regulatory Oversight
503A: Primarily regulated by state boards of pharmacy. FDA oversight is limited — 503A pharmacies are exempt from FDA drug registration, cGMP requirements, and labeling provisions. Quality standards vary significantly by state and by pharmacy.
503B: Registered with the FDA, subject to regular inspections, must comply with cGMP, and must report adverse events. This is a substantially higher regulatory bar.
What this means for telehealth: 503B facilities offer more standardized quality assurance. When evaluating a 503A partner, ask about their internal quality systems — USP 795/797 compliance, testing protocols, and QC procedures. A good 503A pharmacy will voluntarily hold itself to standards approaching 503B requirements.
What They Can Compound
Both facilities are limited by separate FDA "bulks lists":
503A Bulks List: Categories 1 (eligible), 2 (not eligible), and 3 (under evaluation). The February 2026 Kennedy reclassification primarily affects this list.
503B Bulks List: Has its own Category 1/2/3 system that doesn't perfectly mirror the 503A list. For example, GHRP-2 was recently moved to Category 1 on the 503B list for non-injectable routes — while remaining different on the 503A list.
What this means for telehealth: Don't assume that because a peptide is Category 1 for 503A, it's automatically available through 503B (or vice versa).
Biologics Limitation
Substances with 40 or more amino acids are classified as biologics, not drugs. Neither 503A nor 503B facilities can compound biologics. All commonly used telehealth peptides (BPC-157, CJC-1295, Ipamorelin, Thymosin Alpha-1, etc.) are under 40 amino acids and within compounding authority.
Distribution and Shipping
503A: Compounds ship directly to the patient or prescriber's office. Interstate distribution requires state-by-state pharmacy licensing. Many 503A pharmacies hold licenses in multiple states for national telehealth companies.
503B: Can distribute batch quantities to healthcare facilities across state lines without individual prescriptions. Primary advantage for clinic-based models.
What this means for telehealth: For DTC models, the 503A pharmacy handles medication fulfillment. Your kitting partner handles packaging and injection supplies. Coordinating these two shipment streams is one of the key operational challenges.
Which Model Fits Your Telehealth Program?
DTC Peptide/GLP-1 Programs → 503A
If patients receive compounded medications shipped home based on a telehealth prescriber's Rx, you need 503A pharmacy partners. This is the dominant model for weight management, peptide therapy, and hormone optimization programs.
Operational considerations: You need a pharmacy licensed in every state you serve, with established API supplier relationships, scalable compounding capacity, and coordination with your fulfillment/kitting partner.
Clinic-Based Administration → 503B (or 503A)
If providers administer compounds in-office, 503B facilities can supply batch quantities. This simplifies cold chain (shipping to a facility with refrigeration) but adds inventory management complexity.
Hybrid Models → Both
Many telehealth companies operate both DTC and clinic-based programs, partnering with both 503A pharmacies and 503B facilities. Operationally heavier but maximally flexible.
Evaluating a 503A Pharmacy Partner
Licensing footprint: How many states do they hold active pharmacy licenses in? Can they serve your entire patient geography?
Peptide compounding capabilities: Do they currently compound your formulary peptides? Post-reclassification, do they have API supplier relationships to resume compounding quickly?
Quality systems: USP 795/797 compliance, potency testing, sterility testing, endotoxin testing, beyond-use dating studies?
Capacity and scalability: Current volume? Can they 2x or 5x? Typical turnaround time?
Fulfillment coordination: Will they coordinate with your kitting partner? Can the compound ship into your kitting facility for combined kit assembly?
Technology: API or portal for prescription submission? Real-time order tracking? Refill management?
The Regulatory Landscape Is Still Moving
The 503A/503B framework isn't static. The Kennedy reclassification is the most dramatic recent shift, but the FDA continues to evaluate both bulks lists. State pharmacy boards also layer on their own requirements.
Build regulatory monitoring into your operations. Track Category 1/2/3 changes. Ensure your pharmacy partner has compliance counsel who stays current on both federal and state-level changes.
The providers who navigate this well will have a significant competitive advantage. The ones who ignore it will eventually face a compliance surprise they weren't ready for.